A Randomized, Open-label, Two-period Crossover Bridging Study on Fuzuloparib Capsules of Different Specifications in Healthy Chinese Volunteers.
Sign Up to like & getrecommendations! Published in 2021 at "British journal of clinical pharmacology"
DOI: 10.1111/bcp.15035
Abstract: INTRODUCTION Fuzuloparib, also known as fluzoparib or SHR3162, is a poly ADP-ribose polymerase (PARP) inhibitor developed for the treatment of malignant tumor. Three specifications of fuzuloparib capsules (10mg, 40mg and 100mg) were originally developed for… read more here.
Keywords: randomized open; fuzuloparib capsules; period; study ... See more keywords